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Abstract
Antigen presentation by HLA class I (HLA-I) and HLA class II (HLA-II) complexes is achieved by proteins that are specific for
their respective processing pathway. The invariant chain (Ii)-derived peptide CLIP is required for HLA-II-mediated antigen
presentation by stabilizing HLA-II molecules before antigen loading through transient and promiscuous binding to different
HLA-II peptide grooves. Here, we demonstrate alternative binding of CLIP to surface HLA-I molecules on leukemic cells. In
HLA-II-negative AML cells, we found plasma membrane display of the CLIP peptide. Silencing Ii in AML cells resulted in
reduced HLA-I cell surface display, which indicated a direct role of CLIP in the HLA-I antigen presentation pathway. In HLA-I-
specific peptide eluates from B-LCLs, five Ii-derived peptides were identified, of which two were from the CLIP region. In
vitro peptide binding assays strikingly revealed that the eluted CLIP peptide RMATPLLMQALPM efficiently bound to four
distinct HLA-I supertypes (-A2, -B7, -A3, -B40). Furthermore, shorter length variants of this CLIP peptide also bound to these
four supertypes, although in silico algorithms only predicted binding to HLA-A2 or -B7. Immunization of HLA-A2 transgenic
mice with these peptides did not induce CTL responses. Together these data show a remarkable promiscuity of CLIP for
binding to a wide variety of HLA-I molecules. The found participation of CLIP in the HLA-I antigen presentation pathway
could reflect an aberrant mechanism in leukemic cells, but might also lead to elucidation of novel processing pathways or
immune escape mechanisms.
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Introduction
In immune surveillance against invading pathogens and tumor
cells, antigen processing and presentation by HLA molecules is
essential for induction of potent T cell-mediated immunity.
Classically, exogenously derived antigens, such as bacterial
components, are processed in the endosomal/lysosomal system for
loading onto HLA class II (HLA-II) complexes. After synthesis in
the endoplasmic reticulum (ER), the HLA-II heterodimer binds to
the invariant chain (Ii) for transport to late endosomes [1]. Here, Ii
is cleaved until only a small fragment, the class II-associated
invariant chain peptide (CLIP) remains bound to the class II
peptide-binding groove [2]. In MHC class II loading compart-
ments (MIICs), CLIP is exchanged for an antigenic peptide with
aid of HLA-DM [3,4], and HLA-II/peptide complexes are
exported to the plasma membrane and presented to CD4
+ T
cells. In tumor cells that have APC function, efficient processing of
endogenous, potentially tumor-associated antigens (TAAs) is
pivotal for T cell priming of and/or recognition by specific
effector T cells. We and others previously showed that such
endogenous antigen presentation can also involve HLA-II
complexes [5,6]. Ii silencing in certain tumor cells downmodulates
CLIP, but not HLA-II expression levels [7] and results in
increased presentation of endogenous antigens and tumor-specific
CD4
+ T cell activation [5,8]. These studies contradict with the
proposed requirement of Ii for HLA-II stabilization and transport
[9], but agree with its function in preventing binding of
endogenous peptides to HLA-II complexes in the ER [10].
For HLA-I antigen presentation, endogenous proteins, e.g.
tumor- and virus-associated proteins, are normally degraded by
the cytoplasmic proteasome followed by translocation of peptides
into the ER via the transporter associated with antigen processing
(TAP) molecule. Here, peptides with the appropriate binding motif
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b2m heterodimers and are transported to the plasma membrane
for presentation to CTLs (reviewed in [11]). Professional APCs,
including macrophages, dendritic cells (DCs) and B cells, have
well-equipped machinery to detect, internalize and process
exogenous antigens. These antigens are processed for HLA-II-
mediated presentation, but can also be routed for presentation by
HLA-I, resulting in cross-priming of CTLs (reviewed in [12]). Two
general routes for this so-called cross-presentation have been
described: exogenous antigens are degraded and directly loaded
onto HLA-I molecules in the endo-lysosomal pathway [13] or,
alternatively, gain access to the cytoplasm for proteasome-
dependent processing and are directed either back into endosomes
or the ER via TAP [14,15]. The precise mechanism by which
HLA-I molecules may enter the endo-lysosomal pathway is poorly
defined.
Ii is a type II transmembrane protein that exists in different
isoforms and contains one or more internal targeting signals for
specific transport of newly synthesized HLA-II complexes to the
MIICs [16,17]. In addition to its role in HLA-II transport, the role
of Ii as chaperone seems to be more versatile. Ii binds to the actin-
based motor protein myosin-II to negatively affect DC migration
[18], to adhesion molecule CD44 to activate T cells [19] as well as
to costimulatory molecule CD70 for targeting to the MIICs [20].
In the present study, we show an accessory role for Ii and CLIP in
HLA-I processing and antigen presentation by leukemic cells.
Methods
Patient Material
Bone marrow samples from nine newly diagnosed acute
myeloid leukemia (AML) patients were collected after obtaining
written informed consent and according to the Declaration of
Helsinki. This was approved by the review board (‘Medisch
Ethische Toetsingscommissie, METc’) of the VU University
Medical Center, Amsterdam, The Netherlands. Classification of
acute promyelocytic leukemia (APL) was based on standard
genetic and molecular detection of t(15;17), as part of routine
diagnostic procedures at our department. HLA-DR-negative
AML patients contained high numbers of myeloid cells (.80%
of the total WBC count), which were defined as CD45
dim/
SSC
low-int by flow cytometry. Mononuclear cells were isolated
using Ficoll-PaquePLUS (Amersham Biosciences, Freiburg,
Germany) and directly used for protein analysis or cryopre-
served in liquid nitrogen.
Cell Lines and Culturing
Human leukemic cell lines KG-1, THP-1 and Kasumi-1 were
purchased from the American Type Culture Collection (ATTC).
KG-1 cells were maintained in IMDM (Gibco, Paisley, UK)
supplemented with 20% FBS (Greiner, Alphen a/d Rijn, The
Netherlands), 25 mM Hepes (Sigma-Aldrich, St Louis, MO,
USA), 1% L-glutamine and 50 mM 2-ME (both Gibco). THP-1
and Kasumi-1 were cultured in RPMI 1640 medium (Gibco)
containing 10% and 15% FBS, respectively. For peptide elutions,
Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cell lines
(B-LCLs) were generated from peripheral blood mononuclear cells
(PBMC) from healthy blood donors or patients. This was
performed in approval with the Leiden University Medical Center
review board. EBV-transformed B-LCL JY, PHEB and 5544 were
cultured in IMDM containing 8% FBS, 100 IU/ml penicillin and
2 mM L-glutamine. For the competition-based peptide binding
assays, B-LCLs expressing HLA-I alleles of interest were a
generous gift from Dr. J. Kessler (Leiden University Medical
Center; [21]). T2 cells were obtained from Dr. P. Cresswell (Yale
University School of Medicine, New Haven, CT, USA).
Antibodies and Immunofluorescence Stainings
We used the following mouse anti-human monoclonal antibod-
ies (MoAbs): PE-labeled anti-CLIP (clone cerCLIP.1; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and anti-HLA-ABC (clone
W6/32; Dako, Glostrup, Denmark); FITC-labeled CD74, anti-
HLA-DR (clone L243) and anti-HLA-DRPQ; PerCP-labeled
CD45 (all BD Biosciences, San Jose, CA, USA). Anti-Ii MoAb
(clone PIN1.1) was kindly provided by Dr. P. Cresswell. For
stainings of murine cells, PE-labeled CD8 (clone 53–6.7;
Biolegend, San Diego, CA, USA) and APC-labeled anti-IFN-c
(clone XMG1.2; BD Biosciences) antibodies were used.
For immunofluorescence, cells were incubated with 10%
human c-globulin (60 mg/ml; Sanquin, Amsterdam, The Nether-
lands) before the MoAb of interest was added. Moabs were added
during 15 min at room temperature (RT). Intracellular staining for
Ii was performed on cells fixed with PBS 1% paraformaldehyde
and permeabilized with PBS 0.1% saponin (Sigma-Aldrich). After
incubation with PIN1.1 for 30 min at RT, cells were stained for
20 min with a secondary, PE-labeled rabbit anti-mouse (RAM)
IgG (Dako). Each incubation step was followed by two washing
steps in PBS with 0.1% HSA and 0.05% sodium azide. We used a
FACSCalibur flow cytometer and CellQuestPro software (BD
Biosciences) or Flowjo software (Treestar Inc, Ashland, OR, USA)
to analyze the percentage of positive cells. Leukemic cells of AML
patients were defined by CD45
dim/SSC
low expression.
Co-immunoprecipitations and Western Blotting
See File S1 in the Supporting Information section.
Retrovirus Production and Transduction
Ii expression was silenced using the retroviral pSIREN-RetroQ
vector (Clontech, Palo Alto, CA, USA) consisting of a puromycin
resistance gene together with a cloned Ii siRNA insert (sequence
no. 53; [22]) Retrovirus, a kind gift from Dr. S. Ostrand-
Rosenberg (University of Maryland, Baltimore, USA), was
produced as reported [23]. For retroviral transduction, 1610
6
cells/ml were cultured until 40% confluency. Following washing
with PBS, cells were resuspended in DMEM (Gibco) containing
10% FBS, 10 mM Hepes and polybrene, followed by the drop-
wise addition of retroviral supernatant to attain a polybrene
concentration of 4 mg/ml. Cells were incubated at 37uC for 6 h,
washed three times with excess PBS and kept in culture medium
for three days. Subsequently, 0.5 mg/ml puromycin was added
and increased gradually during a period of two weeks to a final
concentration of 1.0 mg/ml in order to select Ii siRNA-transduced
cells. Ii expression in transduced cells was checked by flow
cytometric analysis. The process of siRNA formation and
retroviral transduction itself was validated not to affect Ii
expression [6,22].
HLA Class I Peptide Isolation, HPLC and Mass
Spectrometry
HLA-I/peptide complexes were purified from .10
10 EBV-
transformed B-LCLs by affinity chromatography using protein A
beads (GE Healthcare) covalently bound to MoAbs against HLA-I
(clone W6/32; used for B-LCL JY) or HLA-A2 (clone BB7.2; [24];
used for B-LCL PHEB and 5544). Peptides were eluted from
isolated HLA-I molecules and separated from class I heavy chains
and b2m by passage through Centriprep filtration units with a
10 kD, and the complex peptide pool was fractionated on a
Invariant Chain and CLIP Association with HLA-I
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packed in house. The gradient was run from 0% to 50% solvent B
(10/90/0.1 v/v/v water/acetonitrile/formic acid) in 45 min.
Peptide fractions from the first dimension separation were
reduced to near dryness and resuspended in 95/3/0.1 v/v/v
water/acetonitrile/formic acid. These resuspended fractions were
analyzed by on-line nano-HPLC mass spectrometry using a system
earlier described [25]. Fractions were injected onto a precolumn
(100 mm615 mm; Reprosil-Pur C18-AQ 3 mm, 5 mm, Phenom-
enex) and eluted via an analytical nano-HPLC column
(15 cm650 mm; Reprosil-Pur C18-AQ 3 mm). The gradient was
run from 0% to 50% solvent B (10/90/0.1 v/v/v water/
acetonitrile/formic acid) in 90 min. The nano-HPLC column
was drawn to a tip of approximately 5 mm and acted as the
electrospray needle of the MS source.
For mass spectrometry, we used a LTQ-FT Ultra mass
spectrometer (Thermo, Bremen, Germany) that was operated in
data-dependent mode, automatically switching between MS and
MS/MS acquisition. Full scan mass spectra were acquired in the
Fourier-transform ion cyclotron resonance (FT-ICR) with a
resolution (m/Dm at full width half maximum) of 25,000 at a
target value of 5,000,000. The two most intense ions were then
isolated for accurate mass measurements by a selected ion
monitoring scan in FT-ICR with a resolution of 50,000 at a
target accumulation value of 50,000. The selected ions were then
fragmented in the linear ion trap using collision-induced
dissociation at a target value of 10,000. In a post analysis process,
raw data were converted to peak lists using Bioworks Browser
software, Version 3.1. For peptide identification, MS/MS data
were submitted to the human IPI database using Mascot Version
2.2.04 (Matrix Science) with the following settings: 2 ppm and 0.8-
Da deviation for precursor and fragment masses, respectively; no
enzyme was specified. Mascot output files were loaded into
Scaffold (http://www.proteomesoftware.com) and exported to
Excel.
HLA Class I Binding Prediction and Synthesis of Peptides
The capability of peptides to bind to which HLA-I molecules
was predicted via the netMHC server (http://www.cbs.dtu.dk/
services/NetMHC; [26,27]), which makes use of approximation
algorithms via artificial neural networks (ANNs) and is trained on
9- to 11-mer peptides to predict binding to HLA-I antigen binding
pockets. Predicted peptides were synthesized by standard Fmoc
chemistry and using a Syro II peptide synthesizer (MultiSyntech,
Witten, Germany), as described previously [28]. The integrity of
each peptide was routinely validated by HPLC and mass
spectrometry.
Competition-based Cellular Peptide Binding Assay
To test binding affinity of eluted and predicted peptides to
HLA-I, competition-based cellular peptide binding assays were
performed as described earlier [21]. In short, B-LCLs were treated
with a mild acid (1:1 mixture of 0.263M C6H8O7*H2O and
0.126M Na2HPO4*2H2O) for 1 min to remove the naturally
HLA-I bound peptides. Cells were buffered with cold IMDM
containing 2% FCS immediately thereafter and resuspended at a
concentration of 4610
5 cells/ml in 2% FCS and 1.5 mg/ml
human b2m (Sigma-Aldrich). Then, 4610
4 cells/well were
incubated with 150 nM of fluorescently labeled reference peptide
and a serial dilution of one of the eluted or predicted peptides. The
following HLA-I allele-restricted reference peptides were used:
FLPSDCFPSV (for HLA-A0201), KVFPCALINK (for HLA-
A0301), APAPAPCWPL (for HLA-B0702) and GEFGGCGSV
(for HLA-B4002), each containing a fluorescent label bound to the
cysteine residue [21]. After overnight incubation at 4uC, cells were
washed twice in PBS supplemented with 1% BSA and fixed in
0.5% paraformaldehyde. Cells were analyzed with CellQuestPro
or FlowJo software (Tree Star, Ashland, OR, USA). IC50 values
were defined with GraphPad Prism 4.02 (GraphPad Software Inc.,
La Jolla, USA) using the following formula: Y=Bmax*X/
(IC50+X), in which Bmax is the maximal binding capacity of
the positive control peptide, X the concentration of peptide tested
and IC50 the concentration of peptide needed to reach half-
maximal binding.
Mouse Immunizations
HLA-A2 transgenic mice (B6 background HLA-A2/H2-D;
[29]) were immunized subcutaneously with 50 mg of invariant
chain peptides and 150 mg HBV T helper peptide (TPPAYRPP-
NAPIL) in PBS. The injection side was covered with 60 mg of
Aldara cream containing 5% imiquimod (3 M Pharma Nederland
BV). Immunization was repeated on day 7 combined with two
intraperitoneal injections of 600.000 IU human recombinant IL-2
(Novartis) on day 7 and 8 [30]. The predicted invariant chain
peptides were pooled to a total of 50 mg each. As positive control,
mice were injected with 50 mg of MLIVYVRFWWL. At day 13,
blood samples were taken and tested for CD8
+ T cell reactivity by
overnight incubation with the corresponding peptide and
intracellular staining for IFN-c.
Results
CLIP Presented on HLA-DR-negative Leukemic Cells from
Patients is not Explained by Plasma Membrane
Expression of HLA-II or CD74
We found that patients with acute promyelocytic leukemia
(APL; [31]), a genetically determined subtype of HLA-DR-
negative acute myeloid leukemia (AML), contained a high
frequency of leukemic cells with surface display of the CLIP
epitope. Since CLIP expression was not observed on normal
promyelocytes from healthy individuals, this remarkable observa-
tion may suggest that CLIP presentation at the plasma membrane
of these leukemic cells is leukemia-specific and occurs in the
context of other types of HLA-II proteins or as unprocessed Ii. To
examine the underlying mechanism of CLIP presentation, we
analyzed protein expression of total HLA-II and CD74 (i.e.
unprocessed Ii) at the plasma membrane. Flow cytometric analysis
however showed a lack of both proteins on HLA-DR
2CLIP
+
leukemic cells (Figure 1A and B), which shows that the expression
of CLIP can neither be attributed to its presentation by HLA-DP
or HLA-DQ molecules, nor to the expression of unprocessed Ii.
Invariant Chain Silencing in Myeloid Leukemia Cell Lines
Differentially Influences HLA-I Surface Expression
In the mutant TAP- and HLA-II-deficient T2 cell line, the
precursor of CLIP, Ii, was shown to interact with H-2D
b alleles
[32]. In addition, Ii can transport HLA-I molecules to endosomal
compartments where exogenous peptides are present [33]. We
next investigated whether there was a relation between Ii and
HLA-I cell surface expression in CLIP-presenting and non-
presenting leukemic cells. Retroviral introduction of Ii-specific
siRNAs strongly downmodulates CLIP expression on several
myeloid leukemia cell lines, as we recently reported [7]. When
these cell lines were assessed for HLA-I protein expression by flow
cytometry, KG-1 cells, which present low surface levels of CLIP
[34], revealed hardly any effect of Ii silencing (Figure 1C). In
THP-1 cells, which highly express CLIP [34], however, silencing
Invariant Chain and CLIP Association with HLA-I
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(Figure 1C). In addition, we found indications that Ii was indeed
able to associate with HLA-I-related products in leukemic cells,
since Ii isoforms were present in HLA-I and Ii immunoprecipitates
(Figure S1A), respectively. This was mostly seen in Ii-overexpress-
ing Kasumi-1 cells (Figure S1A and S2), which also showed an
increase in free-form b2m after Ii silencing (Figure S1B). The
involvement of Ii in HLA-I plasma membrane expression in CLIP-
Figure 1. Surface display of the CLIP epitope on HLA-II-negative leukemic cells and influence of the invariant chain on HLA-I
expression. (A) Surface expression of CLIP, HLA-DR, total HLA-II (‘HLA-DRPQ’) and invariant chain (‘CD74’) of myeloid cells from an acute
promyelocytic leukemia (APL) patient, as determined by flow cytometry. Myeloid cells were defined as CD45
dim/SSC
low/int and expression thresholds
were set according to unstained myeloid cells. (B) Quantitative analysis on frequencies of myeloid cells from APL patients that express CLIP (n=9),
HLA-DR (n=9), total HLA-II (n=6) and CD74 (n=6). Frequencies indicate percentage tumor cells that reach threshold expression based on unstained
leukemic cells. (C) The effect of invariant chain Ii down-modulation in KG-1 (CLIP
-) and THP-1 (CLIP
+) leukemic cells on HLA-I expression at the cell
surface. Intracellular staining (ICS) of Ii (PIN1.1) and surface staining of HLA-I (W6/32) were compared between Ii siRNA-transduced and non-
transduced cells.
doi:10.1371/journal.pone.0034649.g001
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expression of CLIP and HLA-I molecules. Also TAP expression
was limited in CLIP
+ THP-1 cells, in contrast to CLIP
– KG-1 cells
(Figure S2), indicating that the involvement may rely on the ability
to process endogenous antigens for loading in the ER.
Peptides Derived from the Invariant Chain are Presented
at the Cell Surface by HLA-I Molecules
We next assessed whether HLA-I molecules can indeed present
Ii-derived peptides at the plasma membrane. The peptide
repertoires of HLA-I molecules on EBV-transformed B cells,
including CLIP-positive JY cells (Figure S3) were evaluated
through biochemical purification. Out of the total characterized
peptide repertoire, five peptides were derived from the Ii protein
(Figure 2 and Table 1), the sequences of which were validated by
mass spectrometry according to their synthetic counterparts.
Remarkably, two peptides were located within or near the CLIP
region, known for its association with HLA-II peptide-binding
grooves. Isolation of the 5 identified peptides was restricted to
HLA-A0201 and HLA-B0702 alleles presented on EBV-trans-
formed B cells. To examine the HLA-I allele specificity and
binding affinity of these peptides, competition-based peptide
binding assays were performed (Table 1). Four out of five peptides
had binding capacity to the B0702 allele and three of these were
even categorized as high affinity binders. Notably, peptide 1 and
peptide 3, the peptide located within the CLIP region, also bound
to the A0201 allele, which might suggest a promiscuous binding
capacity of these peptides to HLA-I. Altogether, these data
demonstrate that surface HLA-I molecules are able to present a
variety of peptides generated from Ii.
Invariant Chain-derived Peptides Located at the CLIP
Region Show Promiscuous Binding to Various HLA-I
Alleles
As CLIP is known to bind promiscuously to the binding
groove of a broad range of HLA-II molecules [35], we further
explored the HLA-I binding specificity of the eluted peptide
located at the CLIP region of Ii (peptide no. 3; Figure 2 and
Table 1). This naturally presented peptide (RMATPLLM-
QALPM) demonstrated a high affinity for both HLA-A0201
and -B0702 (Table 1). To determine if peptide RMATPLLM-
QALPM could bind promiscuously to HLA-I molecules, we
addressed its binding capacity to HLA-I molecules bearing
structurally different binding grooves. HLA-I molecules are
classified according to overlapping binding repertoires and
consensus structures in the main peptide binding pockets, so-
called supertypes [36]. HLA-A0201 and -B0702 are well known
representatives of the A2 and B7 supertype, respectively. The
same accounts for HLA-A0301 and -B4002, which represent the
common supertypes A3 and B40 [36]. Interestingly, peptide
RMATPLLMQALPM bound with a relatively high affinity to all
four HLA-I alleles (Figure 3), which have completely different
peptide-binding grooves, suggesting that the CLIP sequence
involved in promiscuous HLA-II binding also underlies a
promiscuous binding to HLA-I molecules.
The unexpected promiscuous binding of peptide
RMATPLLMQALPM to distinct HLA-I molecules prompted
us to systematically assess length variants of peptides located in
the CLIP region of Ii for such binding feature. The CLIP amino
acid sequence of Ii was subjected to standard HLA-I binding
prediction algorithms for 9- to 11–mer peptides [26,27], which
resulted in highly predictive values of three length variants (9-,
10- and 11-mer) of the naturally presented 13-mer
RMATPLLMQALPM (Table 2). The three peptides were
predicted to selectively bind to HLA-A2 subtypes and, in case
of the 11-mer, also to -B7 subtypes. Subsequently, we tested
these predicted peptides for actual binding to our selected alleles
representing four different supertypes, HLA-A0201, -B0702, -
A0301 and -B4002. In contrast to their predictions, all the length
variants bound to each of the four HLA-I alleles with reasonably
high affinity (Table 2), indicating that peptides located in the
CLIP region of Ii have universal binding abilities to polymorphic
HLA-I molecules. Finally, we tested whether the identified Ii-
derived peptides were immunogenic in the context of HLA-I, as
reported for self peptides termed T-cell epitopes associated with
impaired peptide processing (TEIPPs; [37–39]), but immuniza-
tions of HLA-A2 transgenic mice with these peptides showed no
CD8
+ CTL responses (Figure S4). From these data, we conclude
that the CLIP region of Ii harbors a unique peptide sequence
Figure 2. Invariant chain-derived peptides identified in isolated HLA-I molecules of B-LCLs. Peptide elutions of purified HLA-I molecules
from EBV-transformed B-LCLs resulted in the identification of five peptides originating from the invariant chain. HLA-I purification and subsequent
mass spectrometry analysis are described in Materials and Methods. Of note, peptide 3 and 4 are located in the CLIP region, known for universal
binding to HLA-II molecules.
doi:10.1371/journal.pone.0034649.g002
Table 1. HLA-I binding affinity of eluted peptides derived
from the invariant chain.
HLA-I allele HLA-A201 HLA-B0702
Peptide no.* Peptide sequence IC50
{ Affinity
{ IC50 Affinity
1 SRGALYTGFSIL 10.89 Int 1.39 High
2 LLAGQATT .100 – 40.85 Low
3 RMATPLLMQALPM 13.66 Int 0.36 High
4 LPMGALPQGPM .100 – 0.41 High
5 ETIDWKVFESW .100 – .100 –
*See Figure 2 for amino acid position in the invariant chain protein.
{IC50 is the concentration used to obtain half maximal competition and
represents the mean value of two independent experiments.
{Binding affinity is classified according to the following IC50 cut-off values: high
affinity, #5 mM; intermediate (int) affinity, 5–15 mM; low affinity, 15–100 mM; no
binding, .100 mM [21].
doi:10.1371/journal.pone.0034649.t001
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34649Figure 3. Promiscuous binding of CLIP-peptide to distinct HLA-I alleles, representing four supertypes. The CLIP peptide
RMATPLLMQALPM (peptide 3) was tested for binding affinity in a competition-based cellular peptide binding assay. The four tested HLA-I alleles
(HLA-A0201, -A0301, -B0702 and -B4002) harbor a completely distinct binding pocket and bind different peptide ligands. CLIP peptide shows
intermediate to high binding affinity to all of these. Separate positive control peptides efficiently bind to their respective HLA allele: GILGFVFTL
(A0201 peptide), QVPLRPMTYK (A0301 peptide), SPSVDKARAEL (B0702 peptide) and GEFGGFGSV (B4002 peptide) with IC50 values of 3.7, 0.2, 0.7 and
0.2, respectively [21]. The peptide concentration started at 100 mg/ml for HLA-A0201, -A0301 and -B4002 and 25 mg/ml for HLA-B0702, followed by a
serial dilution of a factor two. Exact IC50 values of the CLIP peptides are depicted in Table 2.
doi:10.1371/journal.pone.0034649.g003
Table 2. HLA-I binding affinity of peptide length variants located in the CLIP region of the invariant chain.
HLA-I allele HLA-A201 HLA-B0702 HLA-A0301 HLA-B4002
Peptide sequence Position
{ Predicted allele
{ IC50
1 Affinity
" IC50 Affinity IC50 Affinity IC50 Affinity
RMATPLLMQALPM* 92–104 NA 13.81 Int 0.36 High 3.35 High 3.43 High
KMRMATPLL 90–98 A0201 10.90 Int 0.47 High 6.43 Int 0.44 High
RMATPLLMQA 92–101 A0201 8.08 Int 7.75 Int 2.45 High 2.05 High
RMATPLLMQAL 92–102 A0201+ B0702 4.49 High 1.85 High 4.28 High 0.48 High
*Peptide found with HLA-I elutions.
{Amino acid (AA) position in the invariant chain protein.
{Predicted HLA-I allele to which the peptide binds. Peptide binding prediction was done with netMHC (http://www.cbs.dtu.dk/services/NetMHC). Binding predictions
can be made for peptide lengths between 8 and 11 for all alleles with a novel approximation algorithm using artificial neural networks trained on 9-mer peptides
[26,27]. Only peptides are shown with a predicted binding affinity of 500 nM or stronger.
1IC50 is the concentration used to obtain half maximal competition and represents the mean value of two independent experiments.
"Binding affinity is classified according to the following IC50 cut-off values: high affinity, #5 mM; intermediate (int) affinity, 5–15 mM; low affinity, 15–100 mM; no
binding, .100 mM [21].
doi:10.1371/journal.pone.0034649.t002
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different grooves of both HLA-I and -II.
Discussion
Processing and presentation of antigens via HLA molecules by
APCs is the key mechanism for generating a specific immune
response against pathogens and TAAs. In normal APCs, Ii and
CLIP have essential roles in the HLA-II antigen presentation
pathway. We and others previously described that in tumor cells
that are able to function as APC, expression of Ii and CLIP could
serve as immune escape mechanism by interference with HLA-II-
mediated TAA presentation [5,8,40]. Here, we reveal that Ii can
also be associated with HLA-I antigen presentation in malignant
cells. This study points at an alternative HLA-I antigen
presentation pathway that may affect current concepts of antigen
cross-presentation and tumor immune escape.
One of the early events during HLA-I processing is the binding
of heavy chains to b2m in the ER. This results in HLA-I
stabilization, appropriate folding and incorporation into the class I
peptide-loading complex, consisting of TAP and other ER-resident
chaperones important for efficient HLA-I peptide loading. Our
observation that Ii is involved in HLA-I processing in leukemic
cells (Figure 1C and Figure S1) indicates that it may take part of
this process as well. This agrees with earlier studies using HLA-I-
transfected T2 cells [32,41,42] and suggests that like newly
synthesized HLA-II ab complexes, also HLA-I/b2m heterodimers
can interact with Ii in the ER lumen until peptides are loaded. As
Ii inhibits premature peptide binding to HLA-II complexes in the
ER [10], the question rises how the association of HLA-I with Ii is
related to the function of the class I peptide-loading complex in
this compartment. Ii-silenced THP-1 cells lacking the TAP
molecule (Figure S2) revealed a strong reduction in HLA-I surface
expression level, in contrast to TAP-expressing KG-1 cells
(Figure 1C). Additionally, in transfected TAP-deficient T2 cells,
HLA-I/Ii complexes relied on the absence of TAP-dependent
HLA-I peptides for their stability [32,41] and were also part of the
class I peptide-loading complex [43]. For this, we propose that two
different types of competition mechanisms can be active in APCs:
one involving the binding of Ii to either HLA-I or HLA-II and one
involving the binding of either Ii or peptide loading complex
peptides to HLA. In this model, the balance between TAP and Ii
expression might be of major importance. The likelihood of Ii to
interact with HLA-I molecules increases in the absence of TAP, as
has been described for T2 cells [43], but likely also in the situation
of Ii abundance, as we demonstrate for Ii-high Kasumi-1 cells
(Figure S1 and S2). Our finding that peptides derived from Ii were
predicted and able to bind to HLA-A0201 and -B0702 (Table 1
and Figure 2) further suggests that the peptide-binding groove is
the HLA-I site with which Ii associates. Indeed, mutations in the
binding groove of HLA-B7 molecules affected their interaction
with Ii and expression at the plasma membrane in transfected T2
cells [42]. It remains to be determined which specific HLA-I alleles
are prone to bind to Ii, but the promiscuous binding of CLIP-
related Ii peptides to the four tested HLA-I superfamilies (Table 2
and Figure 3) indicates great similarity to the promiscuous binding
capacity of the CLIP region in the context of HLA-II [44].
However, this contradicts with the large differences in key anchor
motifs between each HLA-I superfamily. The shallow binding
grooves of HLA-II binds peptides based on favorable interactions
rather than need of specific amino acids at each position. Even one
amino acid with high affinity to the HLA-II binding groove is
sufficient for peptide binding, which could also be the case for
HLA-I, as the methionine at position 99 of the CLIP region served
as crucial anchor residue for H2-Kb molecules [43].
The observed involvement of Ii and CLIP in HLA-I processing
in leukemic cells, as the result of a potentially imbalanced TAP/Ii
ratio, can have different outcomes on tumor immune escape. In Ii
overexpressing leukemias, such as AML (e.g. Kasumi-1 cells; Figure
S2) and chronic lymphocytic leukemia (CLL; [45]), but also
colorectal carcinoma [46], Ii instead of TAA-derived peptides may
be bound to HLA-I molecules after synthesis in the ER, thereby
preventing TAA presentation at the plasma membrane and
recognition by TAA-specific CTLs. In TAP-deficient tumors, self
peptides termed TEIPPs have been identified that are specifically
detected by CTLs [37,39]. In addition, we observed a possible
relation of TAP and CLIP expression in leukemia, with CLIP
-
leukemic cells positive and CLIP
+ leukemic cells negative for TAP
(including APL cells in Figure 1A; Figure S2; [6]). Therefore, the
formation of HLA-I/Ii complexes may lead to processing of Ii into
CLIP and surface presentation of this self-peptide as a TEIPP. In
immunized HLA-A2 transgenic mice however, we could not
detect CTL responses against CLIP-related Ii peptides (Figure S4).
Another possibility is that HLA-I/Ii complexes in leukemic cells
are transported from the ER into the endo-lysosomal pathway to
be loaded with TAA-derived peptides obtained from authophagy
and lysosomal processing. In normal APCs, Ii is classically known
for its role in trafficking HLA-II molecules to the MIICs. It was
recently demonstrated that in DCs Ii is also able to direct CD70
molecules to these compartments [20], indicating that the
interaction of Ii with HLA-I molecules could account for such a
transporting function as well and represent a novel cross-
presentation pathway. Sugita and colleagues already demonstrated
a role for Ii in the transport of HLA-I molecules to endosomes
[33], which might explain the accumulation of newly synthesized
HLA-I molecules in endosomal storage compartments [13].
Indeed very recently, in murine DCs, Ii was shown to be critical
in MHC class I trafficking from the ER to late endosomes for
antigen loading, serving as a mediator of cross-presentation [47].
Although further HLA-I/Ii processing for peptide loading in such
endosomal compartments remains undefined, we detected CLIP-
related Ii peptides in HLA-I-specific eluates of B-LCLs (Table 1
and Figure 2), indicating that Ii can be processed to CLIP in HLA-
I. These peptides were not derived from HLA-II molecules, as
validations for contamination with HLA-II during each step of
peptide elution showed HLA-I heavy chains and b2m, but no
HLA-II monomers. It is thus appealing to further examine HLA-I-
mediated exchange of CLIP for antigenic peptides in the endo-
lysosomal pathway as well as presentation of CLIP at the plasma
membrane for the effect on CTL activation.
In this report, we present important data showing the
promiscuous involvement of Ii and CLIP in the HLA-I antigen
presentation pathway of leukemic APCs. To define the similarity
with HLA-II processing, further exploration of their role in
intracellular transport and peptide loading of HLA-I molecules is
necessary. Since Ii and CLIP are involved in both HLA-I and
HLA-II antigen presentation, it will be attractive to design
immunotherapeutic strategies that modulate their expression,
thereby controlling antigen presentation with the purpose to
target immune surveillance against leukemias and possibly prevent
autoimmunity.
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leukemic cells. (A) Immunoblotting of Ii in both HLA-I (W6/
32) and Ii (PIN1.1) immunoprecipitates of KG-1, THP-1 and
Kasumi-1 cells. IgG immunoprecipiates were used as negative
controls. (B) The presence of free-form b2m (12 kD) in total lysates
of leukemic cells derived from the Ii-overexpressing Kasumi-1 cell
line. Immunoblots for Ii and b2m were performed under SDS
conditions and antibodies used for staining were against Ii (PIN1.1)
or b2m (rabbit polyclonal antibody, kindly provided by Dr. J.J.
Neefjes, NKI, Amsterdam, The Netherlands).
(TIFF)
Figure S2 Immunoblot analysis of Ii and TAP expres-
sion in the KG-1 (CLIP
2), THP-1 (CLIP
+) and Kasumi-1
(CLIP
+) leukemic cell line. Blots were loaded with total cell
lysates and stained with primary anti-Ii (clone PIN1.1) and anti-
TAP1 (clone 148.3, a kind gift from Dr. E.J. Wiertz and Dr. M.E.
Ressing, University Medical Center Utrecht, The Netherlands)
MoAb, demonstrating specific bands of 33 kD and 74 kD,
respectively.
(TIFF)
Figure S3 CLIP expression on the surface of T2 and
EBV-transformed JY cells, as determined by flow
cytometry using a PE-labeled cerCLIP.1 MoAb.
(TIFF)
Figure S4 The in vivo effect of Ii-derived peptides on
CD8
+ T cell activation. HLA-A2 transgenic mice (n=3 per
group) were immunized with Ii-derived peptides identified in
peptide elution studies (see Table 1 for numbering), or with a pool
of Ii-derived peptides identified on basis of an in silico prediction
algorithm (see Table 2). After 13 days, peptide-reactive CD8
+ T
cells from blood were stained with PE-labeled CD8 and APC-
labeled anti-IFN-c antibodies and analyzed by flow cytometry.
IFN-c-positive CD8
+ T cell frequencies are expressed as the
percentage within the total pool of CD8
+ T cells.
(TIFF)
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